Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis

Exclusion criteria

• ✕. Medical Conditions
• ✕. Severe disease from TAK for which urgent treatment with interventional vascular procedures or bypass surgery is considered necessary
• ✕. Critical organ involvement of TAK, such as myocardial or coronary artery involvement, or cerebral ischemia, that is anticipated to need treatment during the study
• ✕. Active hepatitis B or C virus infection
• ✕. Active tuberculosis (Patients with latent tuberculosis infection could be enrolled with preventive therapy for tuberculosis flare)
• ✕. Malignancy in the past 5 years (with the exception of fully excised non-melanoma skin cancer or cervical carcinoma in situ)
• ✕. Poorly controlled diabetes
• ✕. Patients with history of venous thrombosis